Mease, P. J.; Chohan, S.; Garcia Fructuoso, F. J.; Gottlieb, A. B.; Chou, R. C.; Mendelsohn, A. M.; Luggen, M. E. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis. J of Skin 2020, 4, s43.